The Board continues to monitor the effect of the Coronavirus (COVID-19) pandemic on IndigoVision’s customers, business and employees. The situation is highly dynamic and IndigoVision is closely following all national government regulations and guidance wherever the Group operates.
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce positive data from its pharmacokinetic (“PK”) study FM58 of MED2002, the Company’s topical gel for erectile dysfunction (“ED”).
At the Annual General Meeting to be held at 11am today, the Board will update shareholders on trading.
IndigoVision is pleased to announce that Vikki Macleod has been appointed to the Board of the Company as a Non-Executive Director with effect from 29 March 2019.
The Board of IndigoVision is pleased to report the financial results for the year ended 31 December 2018.
The Board of IndigoVision is pleased to report that sales for the financial year ended 31 December 2018 were $45.9m, representing a 9% increase over 2017 sales of $42.1m (as restated for the adoption of IFRS 15).